{"entity":{"id":"tempus-xe","kind":"drug","name":"Tempus xE","aka":[],"tldr":"Tempus' tumour test that reads the protein-coding part of every gene, with possible inherited findings reported from a limited list.","summary":"Tempus xE is a whole-exome panel of more than 19,000 genes sequenced from DNA, reporting potentially actionable and biologically relevant alterations and tumour mutational burden. Sequencing of a matched normal sample keeps somatic variant calls accurate, and potential germline findings may be reported from a limited set of 110 genes chosen from ACMG recommendations, NCCN guidelines and published literature; Tempus states that xE is not a validated germline panel and that these findings should not be used to diagnose hereditary cancer risk. It needs a specimen with at least 40% tumour content after macrodissection, and it can be ordered alone or in combination with Tempus xR.","status":"established","asOf":"2026-11-03","links":[{"label":"Tempus: xE (archived copy, 11 April 2026)","url":"http://web.archive.org/web/20260411051124/https://www.tempus.com/oncology/genomic-profiling/xe/"},{"label":"Tempus: xE","url":"https://www.tempus.com/oncology/genomic-profiling/xe/"}],"tags":["test"],"related":["tempus-xt-cdx","tmb-high"],"cancers":[],"sections":[],"technologies":["wes-wgs"],"targets":[],"drugs":[],"companies":["tempus"],"institutions":[],"pathways":[],"terms":["ngs","tmb"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: a tumour alteration linked to a drug or a trial is listed; a possible inherited finding needs confirmation with a dedicated germline test and genetic counselling.","Not confirmed: the regulatory status of xE. Tempus' page does not state it."],"brand":"Tempus xE","modality":"Whole-exome tumour sequencing test (tumour and matched normal)","mechanism":"DNA sequencing of the whole exome, more than 19,000 genes, from tumour tissue with a matched normal sample used to tell tumour-only changes from inherited ones.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tempus-xe/","neighbours":{"drug":[{"id":"tempus-xt-cdx","kind":"drug","name":"Tempus xT CDx","route":"/drugs/tempus-xt-cdx/"}],"biomarker":[{"id":"tmb-high","kind":"biomarker","name":"TMB-high (tumour mutational burden >= 10 mutations per megabase)","route":"/biomarkers/tmb-high/"}],"technology":[{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/"}],"term":[{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/"}]}}